Analysts note Walgreens’ intent with the proposed deal is to keep pace with its rival, Woonsocket, R.I.-based CVS Health, which declared plans to purchase Aetna last year, and possibly head off any threat Amazon may pose if the retail giant enters the drug market. However, analysts speculate the move may prevent Walgreens from engaging in certain opportunities down the line. Any cost-saving potential the deal could provide may also not be realized for some time, as Walgreens is still in the midst of completing its $4.38 billion amended asset purchase agreement with Camp Hill, Pa.-based Rite Aid.
“We’re currently struggling to see the strategic allure of the [AmerisourceBergen] combination for Walgreens,” a Baird analyst told Reuters.
Analysts claim the proposed CVS-Aetna deal will create a healthcare giant and widen CVS’ reach in the market, whereas the proposed Walgreens-AmerisourceBergen deal would not accomplish similar goals for Walgreens, the report states.
The deal would, however, provide Walgreens with a stronger presence in the specialty pharmacy space, competing against CVS and pharmacy benefit manager Express Scripts, analysts claim.
More articles on supply chain:
Leadership shakeout at Axovant — CEO, COO, 3 board members step down: 5 things to know
Recognize 5 types of supply chain leaders in your hospital
NIH funding helped 210 new drugs to the market between 2010 and 2016: 4 findings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
